Transgene Biotek

Transgene Biotek Quick Ratio

The Quick Ratio (Acid Test) of Transgene Biotek (526139.BO) as of Oct 30, 2026 is 0.63. In the previous year, Quick Ratio (Acid Test) was 0.57 — a change of 10.25% (higher).

Quick Ratio

0.63

YoY

10.25%

Last updated:

Quick Ratio (Acid Test) of Transgene Biotek is 2026 0.63 . Quick Ratio (Acid Test) of Transgene Biotek was 2025 0.57 . It decreases by 10.25% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Biotek Stock analysis

What does Transgene Biotek do? Transgene Biotek Ltd. generates revenue through the sale of diagnostic kits and its portfolio of products, including oncology, auto-immunity, drug delivery, and biogenerics solutions. The company offers TrabiAAV, a platform for delivering miRNAs, ShRNAs, and immunogens in gene therapy, and TrabiORAL, which enables oral delivery of proteins and peptides for treating human diseases. Its TBL-1203 product strengthens cell-mediated immunity to eliminate HIV without retroviral therapy, while Tacrolimus suppresses the immune system to prevent organ transplant rejection. These products are targeted at healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The firm’s R&D focus on vaccines, oncology, and new drug delivery technologies supports its product development pipeline. TrabiAAV and TrabiORAL are positioned as innovative delivery platforms, while TBL-1203 and Tacrolimus address specific medical needs in HIV treatment and transplant medicine. The company’s diagnostic kits cater to clinical laboratories and hospitals requiring reliable testing solutions for oncology and autoimmune conditions. Transgene Biotek Ltd. serves healthcare professionals, pharmaceutical firms, and research organizations through its specialized products. Its oncology and auto-immunity kits are used in diagnostic settings, while its therapeutic platforms like TrabiAAV and TrabiORAL support drug development for complex diseases. The company’s focus on biogenerics and novel delivery systems aligns with market demands for cost-effective and targeted therapies. Transgene Biotek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene Biotek stock

Quick Ratio (Acid Test) of Transgene Biotek is 0.63 in 2026.

Quick Ratio (Acid Test) of Transgene Biotek changed from 0.57 to 0.63, representing a 10.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Transgene Biotek since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Transgene Biotek with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Transgene Biotek

All Key Metrics — Transgene Biotek